EFFICACY OF P62-EXPRESSING PLASMID IN TREATMENT OF CANINE OSTEOARTHRITIS PAIN: A PILOT STUDY

Vladimir Gabai¹Evgeny A. Bakin²Maxim Langs³Robert Devlin¹Sergei Krasny⁴Yauheni Baranou⁵Sergei Polyakov⁶Maksim Patapovich⁷Sergey Gvozdev⁸Maksim Kardash⁹Aliaksei Bazyleuski¹⁰Andrei Yeliseyeu¹¹Egor Lelikov¹²Andrei Barodka¹³Alexander Shneider^1*

• ¹CureLab, Boston, United States
• ²Institute of Bioinformatics Research and Education (IBRE), Belgrade, Serbia
• ³Miramonte High School, Orinda, United States
• ⁴N.N. Alexandrov National Cancer Centre of Belarus,, Minsk, Belarus
• ⁵City Clinical Oncologic Centre, Minsk, Belarus
• ⁶N.N. Alexandrov National Cancer Centre, Minsk, Belarus
• ⁷Belarusian State University, Minsk, City of Minsk, Belarus
• ⁸BELVITUNIFARM, Vitebsk, Belarus
• ⁹Vet clinic Dr Vet, Minsk, Belarus
• ¹⁰Dr.A.Bazylevsky vet ctr, Vitebsk, Belarus
• ¹¹Veterinary clinic AZBUKAVET, grodno, Belarus
• ¹²PoliVetClinic, Gomel, Belarus
• ¹³Alpha-Vet unitary entrprise, Minsk, Belarus

Introduction: Osteoarthritis (OA) is a progressive degenerative disease of synovial joints which is highly prevalent in dogs and results in lameness, loss of joint function and mobility, chronic pain, and reduced quality of life. Traditional OA management consist of non-steroidal anti-inflammatory drugs and remains challenging because of significant side effects, thus there is an urgent need for new effective and safe therapeutics for OA. Methods: Here we present the results of our one-arm open-label pilot clinical study of our novel biologics, a DNA plasmid encoding SQSTM/p62, in 17 companion dogs suffering from OA. The dogs were injected intramuscularly with p62-plasmid once a week for 10 weeks, and pain relief was measured by owners weekly before injections using the CBPI (canine brief pain inventory) validated scale. The 11 parameters of CBPI are grouped in three major domains: pain severity score (PSS), pain interference score (PIS) and overall impression of the quality of life (QoL). Results: Treatment with the p62-plasmid improved all 11 parameters of CBPI including PSS, PIS and QoL. Improvement in CBPI was observed after 2-4 weeks of treatment, whereas after 5-6 weeks of the treatment the parameters reached the plateau. After 10 weeks mean PSS score after the treatment decreased from 5.25 to 3.25, PIS score -from 7.0 to 3.27, and number of dogs with excellent and good QoL due to treatment increased from 1 to 12. Overall, the treatment success rate (i.e. a reduction >1 in PSS and > 2 in PIS) was 90%. Importantly, no significant side effects of the p62-plasmid during the whole treatment period were observed. Discussion: In this pilot study Elenagen demonstrated efficacy in treatment of OA pain in dogs without side effects. The study has some limitations: small animal number, lack of longterm follow-up, and the outcome is limited to only one parameter, CBPI. Also in future studies the mechanism of anti-OA effect of p62 plasmid should be addressed.